U.S. Army Awards Pacific Defense Contract for CMFF Mounted Common Infrastructure
The U.S. Army has awarded Pacific Defense a multi-year contract for the Army’s C5ISR Modular Open Suite of Standards (CMOSS) Mounted Form Factor (CMFF) Mounted Common Infrastructure (MCI) —a critical step in the Army’s acceleration of networked warfighting capabilities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251006130032/en/
Pacific Defense Multi-Domain C5ISR
Under the contract from the Program Executive Office C3N, Pacific Defense will deliver CMFF MCI systems beginning in November 2025 to support soldier experimentation, software integration, and user interface development leading to full vehicle-mounted soldier evaluations in 2026. CMFF MCI spans both ground and aviation platforms and includes plans for integration of capability including communications, command and control (C2), assured PNT (APNT), and EW/SIGINT, all integrated into one standardized a-kit vehicle envelope (SAVE) compliant chassis via plug-in-cards. As a CMFF MCI integrator, Pacific Defense will partner with the Army to accelerate mission capability insertion, drawing from a broad array of industry and government sources for critical mission hardware and software modules.
“We look forward to working with the Army to accelerate user adoption, production, and fielding of this critical, strategic technology in light of recent decisions to re-architect and rapidly re-capitalize Command and Control across echelons,” said Travis Slocumb, CEO of Pacific Defense. “Our CMFF MCI core technology enables EW/SIGINT, robust secure transport and networking, high performance tactical edge compute, APNT, and many C2 applications today with easily provisioned plug and play of cards and software into a variety of existing CMOSS chassis products.”
Pacific Defense has successfully delivered over 150 systems in use today across the U.S. and FVEY partner nations, supporting a wide spectrum of C5ISR/EW missions on ground vehicles, high altitude balloons, various airborne platforms, and fixed sites – and will soon extend into Low Earth Orbit (LEO) and Medium Earth Orbit (MEO) domains. As the pace of new emerging threats intensifies, Pacific Defense expects significant growth in deployments through 2026 and beyond.
As a leading member of the 180+ member Sensor Open Systems Approach (SOSA) Consortium, Pacific Defense has developed a robust family of SOSA/CMOSS-based mission systems. These products integrate both government and commercial hardware and software modules, enabling true multi-vendor interoperability. By leveraging SOSA/CMOSS standards, Pacific Defense ensures that its NERVE, SABER and CMFF MCI products remain adaptable, interoperable, upgradeable, and mission-ready across multiple domains, platforms, and mission sets.
Supporting Pacific Defense on the CMFF MCI effort are Thales Defense & Security Inc., BAE Systems, Palantir, MAXISIQ, Regal Technology Partners, and STC, an Arcfield company.
About Pacific Defense
Pacific Defense is purpose-built to drive the open-systems transformation required to unlock rapid innovation and the power of commercial technology. Specializing in C5ISR and Electronic Warfare (EW) solutions for mission-critical environments, Pacific Defense applies MOSA standards to deliver flexible, upgradeable technology that helps warfighters stay ahead of emerging threats. Learn more at www.pacific-defense.com and on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251006130032/en/
Contacts
Pacific Defense Media Contact
Kent Mader
marketing@pacific-defense.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press Release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press Release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press Release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press Release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom